Brent L Wood
机构: Professor of Laboratory Medicine, Childrens Hospital Los Angeles
每年引用次数
引用次数
引用: 42,567
H-指数: 97
I10-指数 : 278
出版物: 626
Expression Differences of Prognostic Biomarkers in Mononuclear Cells (MNCs) and Malignant Blasts of Acute Myeloid Leukemia (AML) Patients
Era L. Pogosova-Agadjanyan , Soheil Meshinchi , Hana Lee , Brent L. Wood
Blood 118 ( 21) 1468 -1468
2011
Improved Post-Induction Chemotherapy Does Not Abrogate Prognostic Significance of Minimal Residual Disease (MRD) for Children and Young Adults with High Risk Acute Lymphoblastic Leukemia (ALL). A Report From Children's Oncology Group (COG) Study AALL0232
Michael J. Borowitz , Brent L. Wood , Meenakshi Devidas , Mignon L Loh
Blood 118 ( 21) 1440 -1440
6
2011
Anti-CD38 Pretargeted Radioimmunotherapy Demonstrates Therapeutic Efficacy In a Human Multiple Myeloma Mouse Xenograft Model
Damian J. Green , Nural N. Orgun , Mark D. Hylarides , John M. Pagel
Blood 118 ( 21) 1842 -1842
1
2011
High-Throughput Sequencing of T-Cell Receptor Gene Loci for Minimal Residual Disease Monitoring in T Lymphoblastic Leukemia
David Wu , Anna Sherwood , Stuart S. Winter , Kimberly Dunsmore
Blood 118 ( 21) 2545 -2545
20
2011
High-Throughput Screening by Flow Cytometry Identifies Reduced Expression of CD48 As a Universal Characteristic of T-ALL and a Suitable Target for Minimal Residual Disease (MRD) Detection
Brent L. Wood , Greg Levin , Megan Wilson , Stuart S. Winter
Blood 118 ( 21) 2547 -2547
2
2011
Lintuzumab and Low-Dose Cytarabine Compared to Placebo and Low-Dose Cytarabine in Patients with Untreated Acute Myeloid Leukemia (AML) 60 Years and Older: Results of a Randomized, Double-Blinded Phase 2b Study,
Jeffrey E. Lancet , Mikkael A. Sekeres , Brent L. Wood , Laurie E. Grove
Blood 118 ( 21) 3613 -3613
6
2011
Flow cytometry for non-Hodgkin and classical Hodgkin lymphoma.
David Wu , Brent L. Wood , Jonathan R. Fromm
Methods of Molecular Biology 971 27 -47
23
2013
Clinical Experience With Modified, Single-Tube T-Cell Receptor Vβ Flow Cytometry Analysis for T-Cell Clonality.
David Wu , Melanie M. Anderson , Megan Othus , Brent L. Wood
American Journal of Clinical Pathology 145 ( 4) 467 -485
6
2016
The value of secondary pathology review.
Lavinia P Middleton , Tinisha L Mayo , Tracy E Spinks , Richard Cheney
Journal of Clinical Oncology 34 ( 7_suppl) 7 -7
11
2016
Hematopoietic Stem-Cell Transplantation Does Not Improve the Poor Outcome of Children With Hypodiploid Acute Lymphoblastic Leukemia: A Report From Children’s Oncology Group
Jennifer L. McNeer , Meenakshi Devidas , Yunfeng Dai , Andrew J. Carroll
Journal of Clinical Oncology 37 ( 10) 780 -789
21
2019
Complete Remissions Observed in Acute Myeloid Leukemia Following Prolonged Exposure to SGN-33 (lintuzumab), a Humanized Monoclonal Antibody Targeting CD33.
Azra Raza , Joseph G. Jurcic , Gail J. Roboz , Michael Maris
Blood 110 ( 11) 159 -159
10
2007
Outcomes of dasatinib plus intensive chemotherapy or stem cell transplant (SCT) for Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) on Children’s Oncology Group AALL0622.
William Birdsall Slayton , John A Kairalla , Kirk R. Schultz , Meenakshi Devidas
Journal of Clinical Oncology 33 10006 -10006
8
2015
Immunotherapy with CD19-specific chimeric antigen receptor (CAR)-modified T cells of defined subset composition.
Cameron John Turtle , Carolina Berger , Daniel Sommermeyer , Tanya Budiarto
Journal of Clinical Oncology 33 3006 -3006
14
2015
Outcomes in children with Down syndrome (DS) and B-lymphoblastic leukemia (B-ALL): A Children’s Oncology Group (COG) report.
Karen R. Rabin , Zhiguo Chen , Meenakshi Devidas , Johann Hitzler
Journal of Clinical Oncology 38 ( 15_suppl) 10510 -10510
1
2020
Outcomes with reduced intensity therapy in a low-risk subset of children with National Cancer Institute (NCI) standard-risk (SR) B-lymphoblastic leukemia (B-ALL): A report from Children’s Oncology Group (COG) AALL0932.
Reuven J. Schore , Anne J. Angiolillo , John A Kairalla , Meenakshi Devidas
Journal of Clinical Oncology 38 ( 15_suppl) 10509 -10509
2020
Improved Survival for Children and Young Adults With T-Lineage Acute Lymphoblastic Leukemia: Results From the Children's Oncology Group AALL0434 Methotrexate Randomization.
Stuart S. Winter , Kimberly P. Dunsmore , Meenakshi Devidas , Brent L. Wood
Journal of Clinical Oncology 36 ( 29) 2926 -2934
162
2018
Gene expression signature associated with in vitro dexamethasone resistance and post-induction minimal residual disease in pediatric T-cell acute lymphoblastic leukemia.
Lauren K Meyer , Cristina Delgado-Martin , Ritu Roy , Benjamin J Huang
Journal of Clinical Oncology 37 10033 -10033
2019
Ten‐Color Immunophenotyping of Hematopoietic Cells
Brent L. Wood
Current Protocols in Cytometry 33 ( 1)
17
2005
Intrachromosomal Amplification of Chromosome 21 Is Associated With Inferior Outcomes in Children With Acute Lymphoblastic Leukemia Treated in Contemporary Standard-Risk Children's Oncology Group Studies: A Report From the Children's Oncology Group
Nyla A. Heerema , Andrew J. Carroll , Meenakshi Devidas , Mignon L. Loh
Journal of Clinical Oncology 31 ( 27) 3397 -3402
84
2013
The impact of initial cerebrospinal fluid (CSF) findings on outcome among patients with NCI standard (SR) and high-risk (HR) B-lymphoblastic leukemia (ALL): A report from the Children’s Oncology Group (COG) Studies AALL0331 and AALL0232.
Naomi Joan Winick , Meenakshi Devidas , Kelly W. Maloney , Eric Larsen
Journal of Clinical Oncology 32 10016 -10016
3
2014